SOX2 and neoplasm: Subgroup analysis was conducted to evaluate the association of c-MET [27,28] and SOX2 [29,31] with the tumor stage, which showed that the odds of early-stage presentation in SOX2 immuno-positive cases are 75% lower compared to immuno-negative cases (OR = 0.25; 95% CI 0.14–0.45, p < 0.00001, I2 = 0%).